Feature Papers 2025

A special issue of Allergies (ISSN 2313-5786).

Deadline for manuscript submissions: 31 December 2025 | Viewed by 2401

Special Issue Editors


E-Mail
Guest Editor
Institut de Recherche et Développement, Faculté de Pharmacie, UMR 152 PharmaDev, Université Paul Sabatier, 35 Chemin des Maraîchers, 31062 Toulouse, France
Interests: food allergy; allergens; epitopes; celiac disease; structural approaches
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria, Madrid, Spain
Interests: plant food allergens (legumes and nuts); reduction of the allergenic potential through processing; proteomic and genomic analysis; detection of nuts allergens by RT-PCR and biosensors in processed foods
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This is a collection of high-quality papers published free of charge in open access form by the Editorial Board Members or invited by the Editorial Office and the Editor-in-Chief. The papers should be research papers (or review papers) with a full and detailed summary of the author's own research carried out to date.

Prof. Dr. Pierre Rougé
Dr. Carmen Cuadrado
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Allergies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • drug allergies
  • allergic skin diseases
  • hypersensitivity
  • allergens
  • food allergy
  • allergic rhinitis
  • occupational allergy
  • environmental allergy
  • prevention of allergic diseases
  • novel therapies
  • drug desensitization
  • natural history of allergic diseases
  • genetic basis
  • allergen immunotherapy
  • prevention & treatment
  • diagnosis & management

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3214 KiB  
Article
Effects of Triacetin on AMPK Activation and Immune Responses in Allergic Contact Dermatitis
by Yukihiro Yoshimura and Momoka Takahashi
Allergies 2024, 4(4), 254-267; https://doi.org/10.3390/allergies4040017 - 16 Dec 2024
Viewed by 1354
Abstract
Background/Objectives: Allergic contact dermatitis (ACD), an inflammatory skin condition, is commonly treated with topical corticosteroids; however, long-term use of these drugs is associated with various risks, such as skin atrophy and steroid resistance. Triacetin (TA), a triglyceride metabolized to acetate, exerts anti-inflammatory affects [...] Read more.
Background/Objectives: Allergic contact dermatitis (ACD), an inflammatory skin condition, is commonly treated with topical corticosteroids; however, long-term use of these drugs is associated with various risks, such as skin atrophy and steroid resistance. Triacetin (TA), a triglyceride metabolized to acetate, exerts anti-inflammatory affects by activating AMP-activated protein kinase (AMPK) and suppressing mast cell degranulation. Here, we aimed to assess the immediate and long-term effects of TA on ACD suppression, focusing on AMPK activation, using a 2,4-dinitrofluorobenzene-induced rodent model. Methods: Various concentrations of TA were topically applied to rats with 2,4-dinitrofluorobenzene-induced dermatitis. Ear thickness was measured, and histological analysis was performed to assess the inflammation, mast cell infiltration, and degranulation in the established models. AMPK activation was analyzed via Western blotting, and TA degradation was assessed via gas chromatography-mass spectrometry. Dorsomorphin (an AMPK inhibitor) was used to evaluate the effects of AMPK on ACD. Results: TA significantly inhibited inflammation and mast cell degranulation in a dose-dependent manner, with 0.25 mmol/L showing the most potent effects. It also activated AMPK activation. Notably, AMPK inhibition reversed the effects of TA. Conclusions: Overall, TA exerted immediate and long-term anti-inflammatory effects via AMPK activation and inhibition of mast cell degranulation, showing potential as a non-steroidal therapeutic for ACD. Full article
(This article belongs to the Special Issue Feature Papers 2025)
Show Figures

Figure 1

Back to TopTop